AG-14361 is a chemical compound that plays an essential role in cancer treatment. It is also known as AG14361 or AG 14361. The molecular formula of this compound is C24H21F3N4O4S, and its molecular weight is 520.51 g/mol. It is an inhibitor of poly(ADP-ribose) polymerase (PARP) enzymes that are responsible for DNA repair. The CAS number of this compound is 328543-09-5.
Top Ten Keywords:
Synonyms: AG14361, AG-14361, AG 14361, 328543-09-5
Health Benefits: AG-14361 has been used primarily in cancer treatment. It is a PARP inhibitor that targets cancer cells with DNA damage, leading to their selective death. PARP inhibitors prevent the cancer cells from repairing DNA damage, leading to apoptosis, the self-destruction of cells. Some specific cancers have a higher likelihood of mutations in the BRCA gene, leading to an increase in DNA damage. PARP inhibitors are effective in these cases.
Potential Effects: AG-14361 has been shown to be highly effective in the treatment of various cancers, including ovarian and breast cancer. Some other types of cancer that are being evaluated for treatment with PARP inhibitors include pancreatic, prostate, and lung cancer. This compound has been shown to be safe and well-tolerated in clinical trials, and it has been approved for use in some countries.
Product Mechanism: AG-14361 is a small molecule inhibitor that selectively binds to PARP enzymes, leading to the inhibition of DNA repair. It works by trapping the PARP enzyme on the DNA strand, preventing its release and interfering with the replication of DNA. This results in an accumulation of DNA damage that leads to the selective death of cancer cells. The selective targeting of cancer cells by PARP inhibitors is due to the fact that cancer cells have higher rates of DNA damage and repair deficiencies.
Safety: AG-14361 has been shown to be safe and well-tolerated in clinical trials, with minor side effects observed. Some adverse reactions associated with the use of PARP inhibitors include nausea, vomiting, fatigue, and anemia. Additionally, there is a risk of developing myelodysplastic syndromes and acute myeloid leukemias with prolonged use. However, these are relatively rare.
Side Effects: AG-14361 is generally well-tolerated, but some side effects have been reported. Common side effects include nausea, vomiting, and fatigue. Less common side effects include headaches, dizziness, and anemia. There is also a risk of developing myelodysplastic syndromes and acute myeloid leukemias with prolonged use.
Dosing Information: AG-14361 dosing varies depending on the type of cancer being treated, the patient's body weight, and their overall health. The drug is typically administered orally, and the dosage ranges from 10 mg to 100 mg per day. The dosing regimen may also vary depending on the patient's response to treatment.
Conclusion: AG-14361 is a small molecule PARP inhibitor that has shown great promise in the treatment of various cancers, including ovarian and breast cancer. It selectively targets cancer cells with DNA damage, leading to their selective death. The compound has been shown to be safe and well-tolerated in clinical trials, and it has been approved for use in some countries. However, there are some side effects associated with its use, and dosing varies depending on the type of cancer being treated. Overall, AG-14361 holds great potential as a targeted therapy for the treatment of cancer, and continued research is ongoing to evaluate its safety and effectiveness.
